“…To address the lack of 3-dimensionality in pharmaceuticals, there have been efforts in academic and industry laboratories to design and synthesize libraries of 3D molecules to be used in drug discovery campaigns. ,,,,, These structures include compounds prepared through diversity-oriented syntheses with a higher than typical number of sp 3 carbons, as well as chiral and spiro centers. Such strategies are often regarded as possible solutions to the over-representation of flat molecules in fragment libraries and drug discovery feedstocks. ,,,,,, To evaluate the success of such approaches, a PMI analysis (Figure ) was carried out on 15 unique fragments from three different reports (Figure S4). ,, These studies each sought to generate organic fragments with high degrees of 3-dimensionality.…”